Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma

Campbell et al. aggregate genomics and transcriptomics data across melanoma datasets, harmonizing molecular and clinical annotation across samples. Immune cell gene expression patterns and tumor mutational burden, as predictors of anti-PD-1 response, are modified by whether the patient previously received anti-CTLA-4 therapy.

Read the full article here

Related Articles